HuCog-5000 HP

Human chorionic gonadotrophin

Anovulatory infertility in female where the cause is secondary & not due to ovarian failure & its administration would form part of recognized treatment regimen involving prior stimulation of follicular maturation & endometrial proliferation w/ menotrophin or any other medication used for stimulation in infertility. Promotion of controlled superovulation in female in medically assisted reproduction programmes in combination w/ FSH or human menopausal gonadotropin (HMG). Hypogonadotrophin hypogonadism, cryptorchism & delayed puberty associated w/ insufficient gonadotrophic pituitary function in male. Induction & maintenance of spermatogenesis in male w/ concomitant menotrophin therapy.

Anovulatory infertility 5,000-10,000 IU following last dose of menotrophin or other drugs used for stimulation in infertility. Promotion of controlled superovulation in medically assisted reproduction programmes in combination w/ FSH or HMG 5,000-10,000 IU 30-40 hr after the last FSH or HMG inj. Hypogonadotrophin hypogonadism 500-1,000 IU IM thrice a wk for 3 wk followed by same dose twice a wk for 3 wk or, 4,000 u IM thrice a wk for 6-9 mth followed by 2,000 u thrice a wk for an additional 3 mth. Deficient spermatogenesis cases Usually 3,000 IU/wk in combination w/ an FSH or HMG prep. Continued for at least 3 mth before any improvement can be expected. Suspend testosterone replacement therapy during this treatment. May sometimes be maintained by HCG monotherapy once improvement is achieved. Delayed puberty associated w/ insufficient gonadotrophic pituitary function 1,500 IU twice wkly for at least 6 mth. Cryptorchidism 4,000 u IM thrice a wk for 3 wk; or 5,000 u IM every other day for 4 inj; or 500-1,000 u IM for 15 inj over a period of 6 wk; or 500 u thrice a wk for 4-6 wk, may repeat series at 1,000-u dosage 1 mth later if not successful.

Hypersensitivity to HCG or any gonadotropins. Tumors of hypothalamus, pituitary glands. Ovarian, uterine or mammary carcinoma. Vag bleeding of unknown cause. Prostate or breast carcinoma (in males).

Females: Risk of developing ovarian hyperstimulation syndrome. W/hold administration in excessive ovarian response. Careful monitoring of estradiol levels & ovarian response, based in ultrasound prior to & during stimulation therapy. Multiple pregnancies, ectopic pregnancy, abortion; congenital malformations after assisted reproductive techniques (ART). Women w/ risk factors for thrombosis eg, personal or family history, severe obesity (BMI >30 kg/m²) or thrombophilia, may have increased risk of venous or arterial thromboembolic events, during or following treatment. Males: Increased androgen production that could aggravate latent or overt cardiac failure, renal dysfunction, HTN, epilepsy or migraine, or recurrence of these conditions. Premature epiphyseal closure or precocious sexual development. Young boys; patients w/ allergic diathesis. Pregnancy & lactation. Childn. Elderly.

Reactions at the inj site: bruising, pain, redness, swelling & itching; edema, tiredness.

Trophic Hormones & Related Synthetic Drugs

G03GA01 - chorionic gonadotrophin ; Belongs to the class of gonadotropins. Used as ovulation stimulants.

Rx